Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Beats Estimates By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) released its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports.

Compass Therapeutics Stock Down 5.9 %

NASDAQ:CMPX traded down $0.10 on Thursday, reaching $1.59. The stock had a trading volume of 668,605 shares, compared to its average volume of 434,151. The company has a market capitalization of $218.77 million, a P/E ratio of -4.47 and a beta of 0.92. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The stock has a fifty day moving average price of $1.75 and a 200-day moving average price of $1.42.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CMPX. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Monday. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.